Observational studyJAMA ophthalmology2026
Ultra-Widefield Fluorescein Angiographic Quantitative Leakage Parameters and Clinical Outcomes in Nonproliferative Diabetic Retinopathy.
Observational study in JAMA ophthalmology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Early Macular Leakage Resolution Is Associated with Extended Faricimab Dosing in Retinal Vein Occlusion: A BALATON/COMINO Post Hoc Analysis.Ophthalmology and therapy · 2026Article
Corrections and comments
- Commented on by
Authors and funding
10 authors.
Funding
Abstract
Importance: This study could facilitate the generation of automated quantitative assessments, providing clinicians and clinical trials with a continuous severity scale of retinal leakage to improve the prediction of future diabetic retinopathy (DR) worsening. Objective: To examine ultra-widefield fluorescein angiography (UWF-FA) retinal leakage associated with DR progression and complications. Design, Setting, and Participants: This cohort study was a post hoc analysis of the DRCR Retina Network Protocol AA clinical trial. Participants were adults with nonproliferative diabetic retinopathy (NPDR). Data was collected from February 2015 to March 2020. Analysis was performed June 2023 to April 2024. Interventions: Treatment of DR or diabetic macular edema was at the investigator's discretion. Main Outcomes and Measures: Time to Diabetic Retinopathy Severity Scale (DRSS) worsening of 2 or more steps, vitreous hemorrhage (VH), and proliferative diabetic retinopathy (PDR) over 4 years. Baseline and 1-year leakage index, calculated as the area with leakage divided by the total area in the analyzable retina on UWF-FA, were evaluated as risk factors. Results: Among 537 eyes (363 participants; mean [SD] age, 61 [12] years; 183 [50%] male, 180 [50%] female), the baseline leakage index (mean [SD], 3.5% [3.9%]) was associated with DRSS worsening over 4 years (hazard ratio [HR] for 1% increase, 1.09; 95% CI, 1.05-1.13; P < .001). At 1 year, 114 of 453 eyes (25%) had an absolute leakage increase 1% or greater from baseline, which was associated with a higher risk of DRSS worsening over 4 years (61% vs 33%; HR, 2.63; 95% CI, 1.90-3.64; P < .001). Baseline leakage and a 1% or greater increase at 1 year were also associated with development of VH and PDR. Conclusions and Relevance: In eyes with NPDR, higher leakage at baseline and an increase from baseline to 1 year were associated with greater risk of DRSS worsening and vision-threatening complications, including VH and PDR. These findings support quantitative leakage assessment at baseline and over time as a promising biomarker for predicting the severity and progression of diabetic retinopathy.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.